

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
December 9, 2019

MRI INTERVENTIONS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction
of incorporation)

001-34822
(Commission
File Number)

58-2394628
(I.R.S. Employer
Identification Number)

5 Musick
Irvine, Ca. 92618
(Address of principal executive offices, zip code)

(949) 900-6833
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	MRIC	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On December 9, 2019, MRI Interventions, Inc. posted an updated investor presentation to its website at <http://ir.stockpr.com/mriinterventions/investor-presentation>. A copy of the investor presentation is being furnished herewith as Exhibit 99.1. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit 99.1 [Investor Presentation dated December 2019](#).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 9, 2019

MRI INTERVENTIONS, INC.

By: /s/ Harold A. Hurwitz
Harold A. Hurwitz
Chief Financial Officer



CLEARPOINT

PRECISE NEURO NAVIGATION & THERAPY

Investor Presentation
Joe Burnett, President & CEO
December 2019






FORWARD LOOKING STATEMENTS

Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from sales of the Company's ClearPoint® Neuro Navigation Platform products; the

Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation Platform products; and estimates regarding the sufficiency of the Company's cash resources. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2018, and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, both of which have been filed with the Securities and Exchange Commission.

Only a fraction of patients with debilitating neurological disorders are being treated surgically **today**

Prevalence of Neurological Disorders



The Movement to Minimally Invasive Procedures has Happened Everywhere Else in the Body

This transition has always had two things in common:

- More patients being treated
- Procedures **enabled by live image guidance**



PRIMARY CHALLENGE

Traditional Stereotactic Neurosurgery is Limited

The Skull is Not 'See Through'

- X-Ray and CT do not show structures of the brain
- Large, Metallic Navigation Frames are not compatible inside an MRI Magnet
- Surgical Image Guidance in the Operating Room is not live but rather 'Co-Registered' to the MRI
- Each Co-Registration calculation introduces error and reduces accuracy




OUR SOLUTION




ClearPoint® Neuro Navigation Platform

An MRI Compatible Navigation System Delivering Live MRI Guidance during the Procedure



Decide, Guide, Treat & Confirm with Sub-millimetric Accuracy



MRIC & ClearPoint: A Proven Platform

Key Products: FDA CE Marked Platforms; More than 3,000 Procedures Performed to Date

HEADQUARTERS
Irvine, CA

EMPLOYEES
40+
19 sales | 19 production & development

2018 REVENUE
\$7.4m


2019 REVENUE FORECAST
\$10.5m – 11.5m^(E)

MARKET CAP
\$54m^(A)

CASH
\$6.2m^(B)

U.S. PATENTS ISSUED
79
+ 29 pending

GROSS MARGIN
64%^(C)



(A) As of November 14, 2019
(B) As of September 30, 2019
(C) For the nine months ended September 30, 2019
(D) 2019 Forecast
(E) As announced via press release November 12, 2019



ClearPoint® is Installed in 57 Active U.S. Clinical Sites and Growing

Strong Commercial
Sales and Clinical
Support Teams
in Place

UC San Francisco
San Francisco VA
Stanford Univ
Lucile Packard (Stanford Children's)
UCSF Benioff Childrens
USC
UC San Diego
Univ of Colo
Univ of Utah
Univ of Arizona
Cook Children's
MD Anderson
Methodist Hosp

Texas Children's Hosp
Riverside
Henry Ford Health System
Nationwide Children's
Children's Mercy
Kansas Univ Med Center
Univ of Wisconsin
Spectrum Health
Ohio State Univ
Cincinnati Children's
Dallas Presby
Univ of Cincinnati
University of Wisconsin

Cincinnati Jewish
Univ of Michigan
Univ of Minnesota Med Ctr
Brigham & Women's
Boston Children's
Mass General
Mt Sinai West
Yale Univ
Univ of Pitt Med Center
Memorial Sloan Kettering
Hackensack Univ Med Center
Cornell
Central Du Page

Nat. Institutes of Health
Nat. Children's Hospital
Children's Hosp of Philadelphia
Univ of Virginia
Emory University
Carillon
Duke University
Children's of Alabama
CHOA Scottish Rite
Willis Knighton
Mayo Clinic Jacksonville
Mayo Phoenix
Dartmouth Hitchcock

University of Pennsylvania HUP
INOVA Fairfax
LeBonheur
Johns Hopkins
Tampa General



Our MRI-Guided therapy platform is currently being used to...

IMPLANT NEURO STIMULATION LEADS

PLACE LASER ABLATION PROBES

DELIVER BIOLOGICS AND DRUGS

MRIC PLATFORM RUNS ON ALL MAJOR SCANNERS

Medtronic

Medtronic VISUALASE

Voyager THERAPEUTICS

SIEMENS

ST. JUDE MEDICAL

MONTERIS MEDICAL

PTC THERAPEUTICS



Boston Scientific

axovant GENE THERAPIES

PHILIPS


NEUROPACE

INTERNATIONAL STEM CELL CORPORATION

IMRIS

BlueRock Therapeutics


Our platform enables choice of precision-guided therapies and services





CLEARPOINT

Hardware & Software | Artificial Intelligence | Robotics

Example: *The Parkinson's Disease Patient* Enabling Surgeons to choose the right tool for the right patient



Growth in Case Volume, Revenue



2019 Forecast Revenue Range of \$10.5 - \$11.5 M, Cases Range of 800-850 as of November 12, 2019

MARKET POTENTIAL FOR PROCEDURES

Included Below Strategic & Focused Expansion to new geographies either direct or through partners
Leverage existing sales channel for other distribution opportunities (i.e. non-neuro CLS Laser Distribution)

GLOBAL SCALE 4
Expansion & Leverage

50,000+ Laser Therapy (LITT) for Neurosurgery existing \$25+ M Market
Neuro Aspiration Market potential > \$100 M

THERAPY 3
Growth from New Markets

50,000+ 20+ Current non-hospital partners
7+ phase I & II Clinical Trials

BIOLOGICS & DRUG DELIVERY 2
Growth from Existing Markets

12,500+ Tumor Biopsy & Ablation
28,000+ LITT and NeuroPace for Epilepsy
15,000+ Deep Brain Stimulation (DBS) for Parkinson's

NEUROSURGERY 1
2018 Base Revenue


Four Pillar Growth Strategy

Target Indications of > 150,000 procedures per year
represents Potential Addressable Market for MRC of \$1B+

2019

2023

Cash Flow From Operations



Executive Summary



Unique Platform technology
enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders



80%+ of forecast revenue from single-use, high-margin disposables



Large, Growing installed base in 55+ of 250+ leading Neurology centers in U.S.



Pipeline of new revenue streams from product improvements, biologic and drug delivery partnerships, and standalone therapy products



Procedure volume has grown 33%+ CAGR from 2013-2018



Total potential addressable market > \$1B for our products and pipeline



A passionate team of embedded scientists and specialists